Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
Helus Pharma (Nasdaq: HELP) appointed Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board. Donohue previously led HR at Intra-Cellular, which grew to 1,000+ employees before being acquired by Johnson & Johnson in April 2025. Durgam helped secure FDA approvals for CAPLYTA. The moves support Helus’ clinical and potential commercialization plans.
How this was made
The 30-second read
Why it matters
The new Chief People Officer and SAB member are positioned to support organizational scaling and CNS scientific/regulatory guidance as the company advances late-stage programs toward potential commercialization.
Market read
This is a company-specific leadership and advisory board update that may modestly support confidence in execution, but it lacks new clinical or regulatory datapoints.
What to watch
Traders may be overlooking that the release is tied to a prospectus supplement framework, but it still contains no quantified milestone timing, trial readout, or funding update.
Background
Helus Pharma is a clinical-stage CNS drug developer (commercial operating name of Cybin Inc.) with Phase 3 HLP003 for adjunctive MDD and Phase 2 HLP004 for GAD.
Ticker impact
Helus Pharma (HELP) appoints Regina Donohue as Chief People Officer and Suresh Durgam to its Scientific Advisory Board.
Likely limited, with any reaction more sentiment-driven than fundamental unless paired with new clinical/regulatory milestones.
The article discloses executive/SAB additions and references prior experience, but provides no new data, guidance, or regulatory decision tied to HELP’s programs.
Market effects
Reinforces competitive emphasis on CNS leadership and commercialization readiness among clinical-stage biotech developers.
No clear regional market linkage beyond Nasdaq-listed biotech sentiment.
Primarily company-specific; SAB expertise is relevant to global CNS regulatory and development strategy but not a disclosed policy shift.
Counterpoint
Leadership hires may be largely incremental and not a substitute for new clinical catalysts; the market may discount the news quickly.
Key entities
- companyHelus Pharma
Nasdaq-listed clinical-stage pharmaceutical company developing serotonergic agonists (NSAs).
- executiveRegina Donohue
Appointed Chief People Officer; previously Chief Human Resources Officer at Intra-Cellular.
- scientific_advisorSuresh Durgam, M.D.
Appointed to the Scientific Advisory Board; CNS drug-development leader involved in FDA approvals for CAPLYTA at Intra-Cellular.
